The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Klein Lawrence Otto since 2019.
This trader's CIK number is 1762583.
At the time of last reporting, Klein Lawrence Otto was the CBO & COO of Crispr Therapeutics Ag. (stock ticker symbol CRSP).
Also see all insider trading activities at Crispr Therapeutics Ag.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | CRSP | 0 | $0 | 0 | $0 | 7,584 | $0 |
| 2021 | CRSP | 0 | $0 | 25,000 | $5,381,950 | 66,260 | $337,635 |
| 2020 | CRSP | 0 | $0 | 95,000 | $6,827,968 | 95,000 | $808,028 |
| 2019 | CRSP | 0 | $0 | 20,000 | $1,000,348 | 20,000 | $117,199 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-03-10 | CRSP | Option Ex | 4,584 | .00 | 0 |
| 2022-03-11 | CRSP | Option Ex | 3,000 | .00 | 0 |
| 2021-12-03 | CRSP | Option Ex | 26,667 | .00 | 0 |
| 2021-09-10 | CRSP | Option Ex | 10,000 | .00 | 0 |
| 2021-03-10 | CRSP | Option Ex | 4,583 | .00 | 0 |
| 2021-01-15 | CRSP | Option Ex | 25,010 | 13.50 | 337,635 |
| 2021-01-15 | CRSP | Sale | 25,000 | 215.28 | 5,381,950 |
| 2020-06-24 | CRSP | Option Ex | 65,088 | 9.21 | 599,785 |
| 2020-06-25 | CRSP | Option Ex | 4,912 | 12.57 | 61,743 |
| 2020-06-24 | CRSP | Sale | 65,088 | 75.91 | 4,940,569 |
| 2020-06-25 | CRSP | Sale | 4,912 | 75.18 | 369,274 |
| 2020-05-11 | CRSP | Option Ex | 25,000 | 5.86 | 146,500 |
| 2020-05-11 | CRSP | Sale | 25,000 | 60.73 | 1,518,125 |
| 2019-07-11 | CRSP | Sale | 8,421 | 50.01 | 421,167 |
| 2019-07-10 | CRSP | Option Ex | 11,579 | 5.86 | 67,852 |
| 2019-07-11 | CRSP | Option Ex | 8,421 | 5.86 | 49,347 |
| 2019-07-10 | CRSP | Sale | 11,579 | 50.02 | 579,181 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Klein Lawrence Otto (CBO & COO of Crispr Therapeutics Ag at the time of this reporting) see the Securities and Exchange Commission (SEC) website.